scientific advisory board
Scientific Advisory Board (SAB)
Dr Tse-wen Chang
Dr Chang started his industrial career as VP Research at Centocor in the US. As co-founder of Tanox and founding father and inventor of Xolair (Omalizumab) he has become very well known in the research field on allergic asthma. He has received many international awards for his work on Xolair. Dr Chang has filled in a diversity of research related roles as president of the Development Center of Biotechnology in Taiwan, Professor at Tsing Hua University and at the Genomic Research Center of the Academica Sinica in Taipei, Taiwan. Nature Biotechnology listed Dr. Chang in a shortlist of “personalities who have made the most significant contribution to biotech in the past 10 years” in 2006. Dr. Chang received a Prize in Biomedical Sciences from the World Academy of Science in 2014. He now works as the founder, president and CEO of Immunwork Inc in Taiwan.
Prof Dr Erik Frijlink
Erik Frijlink is Professor of Pharmaceutical Technology and Biopharmacy at the University of Groningen (RUG) in the Netherlands.
Dr. Frijlink obtained his Ph.D. degree in Pharmaceutical Technology at the RUG. He served for two years as a pharmacist in the Martini Hospital (Groningen, Nl). From 1992 to 1997 he was head of the Pharmaceutical Development Department of Solvay Pharmaceuticals. He has a wide interest and knowledge on various innovative formulations for non-invasive delivery. He is interested in solid oral dosage forms, their technological and biopharmaceutical aspects and gastro-intestinal targeting strategies. Finally, he is interested in development, scale up and quality aspects of pharmaceutical production.
Since 2016 Dr. Frijlink is Director of the Groningen Research Institute of Pharmacy.
Prof Stephen Mahler
Professor Stephen Mahler is a Senior Group Leader at the Australian Institute for Bioengineering and Nanotechnology and Director of the Australian Research Council Training Centre for Biopharmaceutical Innovation (CBI), University of Queensland. Professor Mahler is a biotechnologist with a focus on R&D of recombinant-DNA derived protein biopharmaceuticals, drug delivery systems and nanomedicines. He has a record of translational research success and engages extensively with industry associated with the biomedical sciences both nationally and internationally.
Research within CBI covers three thematic research areas; discovery of new biopharmaceuticals, engineering cells for production of protein-based biopharmaceuticals and advanced manufacturing for industrial production. A current research interest is at the interface of the life sciences and materials science, using a synthetic biology approach for creating novel therapeutic entities as well as new systems for drug delivery.
Prof. Stephen Mahler
Dr Ben Rademaker
Ben Rademaker has over 40 years of experience in drug development and drug formulation. He worked in academia and industry and is the founder and co-owner of InProPharma BV, a Dutch biotechnology research and development organization specializing in services to the biotechnology and pharmaceutical industry for development of generic products, biosimilars and new biological or chemical entities. Ben is one of the inventors of the oral delivery technology of BiOraliX BV.
Dr Ben Rademaker